# Deciphering gene mutations in the efficacy and toxicity of antineoplastic drugs: an oncology pharmacist’s perspective

## TL;DR

This paper reviews how gene mutations affect cancer drug effectiveness and side effects from the perspective of an oncology pharmacist.

## Contribution

It highlights new pharmacogenomic topics and drug approvals that support personalized cancer treatment.

## Key findings

- Pharmacogenomic factors influence drug metabolism and treatment outcomes.
- New drug approvals and regimens emphasize individualized patient care.
- Advancements in pharmacogenomics support tailored cancer therapies.

## Abstract

This article reviews some key emerging pharmacogenomic topics in oncology pharmacy practice.

Publications selected to review were mainly sourced from the new drug approvals by the Food and Drug Administration and the new regimens listed in the National Comprehensive Cancer Network.

Key pharmacogenomic topics were presented, including genetic alterations influencing drug metabolism, drug efficacy, and changes in therapeutic targeting; Relevant clinical updates and advancements were summarized to provide an in-depth understanding.

The abundance of pharmacogenomic measures builds a solid foundation and heralds a paradigm shift toward individualized patient care.